Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”

Detalles Bibliográficos
Autor principal: Ravasio, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350192/
https://www.ncbi.nlm.nih.gov/pubmed/28108893
http://dx.doi.org/10.1007/s12325-017-0479-x
_version_ 1782514611593936896
author Ravasio, Roberto
author_facet Ravasio, Roberto
author_sort Ravasio, Roberto
collection PubMed
description
format Online
Article
Text
id pubmed-5350192
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-53501922017-03-27 Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate” Ravasio, Roberto Adv Ther Letter Springer Healthcare 2017-01-20 2017 /pmc/articles/PMC5350192/ /pubmed/28108893 http://dx.doi.org/10.1007/s12325-017-0479-x Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter
Ravasio, Roberto
Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title_full Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title_fullStr Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title_full_unstemmed Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title_short Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
title_sort comment on “efficacy and treatment costs of monotherapy with bdmards in the treatment of rheumatoid arthritis in patients intolerant to or inappropriate to continue treatment with methotrexate”
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350192/
https://www.ncbi.nlm.nih.gov/pubmed/28108893
http://dx.doi.org/10.1007/s12325-017-0479-x
work_keys_str_mv AT ravasioroberto commentonefficacyandtreatmentcostsofmonotherapywithbdmardsinthetreatmentofrheumatoidarthritisinpatientsintoleranttoorinappropriatetocontinuetreatmentwithmethotrexate

Ejemplares similares